- Home
- ITRM vs DMAC Comparison
ITRM vs DMAC Comparison
Compare ITRM & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- DMAC
- Stock Information
- Founded
- ITRM 2015
- DMAC 2000
- Country
- ITRM Ireland
- DMAC United States
- Employees
- ITRM N/A
- DMAC N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ITRM Health Care
- DMAC Health Care
- Exchange
- ITRM Nasdaq
- DMAC Nasdaq
- Market Cap
- ITRM 40.0M
- DMAC 178.0M
- IPO Year
- ITRM 2018
- DMAC N/A
- Fundamental
- Price
- ITRM $0.94
- DMAC $3.78
- Analyst Decision
- ITRM Strong Buy
- DMAC Strong Buy
- Analyst Count
- ITRM 2
- DMAC 2
- Target Price
- ITRM $7.00
- DMAC $8.00
- AVG Volume (30 Days)
- ITRM 534.3K
- DMAC 310.7K
- Earning Date
- ITRM 08-13-2025
- DMAC 08-06-2025
- Dividend Yield
- ITRM N/A
- DMAC N/A
- EPS Growth
- ITRM N/A
- DMAC N/A
- EPS
- ITRM N/A
- DMAC N/A
- Revenue
- ITRM N/A
- DMAC N/A
- Revenue This Year
- ITRM N/A
- DMAC N/A
- Revenue Next Year
- ITRM $270.19
- DMAC N/A
- P/E Ratio
- ITRM N/A
- DMAC N/A
- Revenue Growth
- ITRM N/A
- DMAC N/A
- 52 Week Low
- ITRM $0.81
- DMAC $2.90
- 52 Week High
- ITRM $3.02
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- ITRM 41.32
- DMAC 48.71
- Support Level
- ITRM $0.91
- DMAC $3.48
- Resistance Level
- ITRM $1.03
- DMAC $3.84
- Average True Range (ATR)
- ITRM 0.04
- DMAC 0.27
- MACD
- ITRM -0.01
- DMAC 0.01
- Stochastic Oscillator
- ITRM 16.28
- DMAC 58.89
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.